Retroscreen Virology purchases ALPHADAS
Wednesday, July 31, 2013
Retroscreen Virology Group, a virology healthcare company, has purchased the ALPHADAS clinical trials software suite to accelerate and reduce the cost of bringing anti-viral drugs, diagnostics and vaccines to market.
ALPHADAS is an eSource clinical research and early phase trials system that is mobile, schedule-driven and provides real-time bedside or station-based direct data capture that eliminates paper-based data.
ALPHADAS will increase efficiencies and quality through direct data captured from Retroscreen instrumentation and manage and monitor samples through the study lifecycle while offering real-time data review.
Retroscreen conducts the Human Viral Challenge Model in a controlled quarantine environment, providing a cost-effective study design which accelerates the selection of a safe and effective dose, and dosing regimen, for a new antiviral drug or vaccine. ALPHADAS will streamline clinical trial research processes across multiple sites.
It also will be used for accelerated recruitment, staff resourcing and site management operations.